| Source publication date | (issue) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Wellness publication |
| Population | Men |
| Source | Life Extension Magazine |
| URL | lifeextension.com/magazine/2026/3/testosterone-on-the-rise (opens in a new tab) |
Specific Claim Evaluated
Optimal testosterone levels may lower the risk of obesity, type 2 diabetes and cardiovascular disease, and low testosterone may be a biological accelerant of aging and chronic disease.
Primary Research Supporting or Contradicting the Claim
In men with impaired glucose tolerance or new type 2 diabetes enrolled in a lifestyle program, testosterone reduced progression to diabetes (Wittert et al., 2021). In TRAVERSE, testosterone did not reduce major adverse cardiac events (Lincoff et al., 2023).
Corrected Evidence-Based Interpretation
Low testosterone is associated with obesity, diabetes and cardiovascular disease, but randomized evidence shows a diabetes benefit only in a selected population with lifestyle intervention and no cardiovascular benefit.
Rationale for Grade
The article presents associations as evidence that raising testosterone prevents disease and applies a single trial's diabetes result to obesity and cardiovascular disease. It also promotes botanical products sold by the publisher without supporting evidence.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32-45. PMID
Supporting excerpt: "reduced the proportion of participants with type 2 diabetes"